CABOZANTINIB, CABOZANTINIB, LANREOTIDE, CABOZANTINIB
LOLA trial
Phase 2 small_molecule active
Quick answer
CABOZANTINIB, CABOZANTINIB, LANREOTIDE, CABOZANTINIB for gastroenteropancreatic (GEP) and thoracic neuroendocrine tumor (NET) is a Phase 2 program (small_molecule) at Fondazione Telethon ETS with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Fondazione Telethon ETS
- Indication
- gastroenteropancreatic (GEP) and thoracic neuroendocrine tumor (NET)
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active